A dominant thread across this cluster is the maturation of dupilumab's clinical development program across a widening spectrum of type 2/eosinophilic inflammatory diseases—COPD (BOREAS, NOTUS), severe asthma with small-airway remodeling (VESTIGE), and severe chronic rhinosinusitis with nasal polyps (EVEREST)—all sponsored jointly by Sanofi and Regeneron Pharmaceuticals. The BOREAS and NOTUS phase 3 trials, run in parallel across dozens of countries, are increasingly analyzed together via pooled intention-to-treat datasets to strengthen statistical power for characterizing dupilumab's efficacy and safety in COPD patients with elevated eosinophils and type 2 signatures. Complementing these outcome-driven trials, VESTIGE represents a mechanistic deep-dive, using functional respiratory imaging, airway oscillometry, spirometry, and FeNO thresholds to demonstrate that dupilumab measurably remodels small-airway structure (mucus plugging, regional airway volumes at total lung capacity), not just symptom scores. Meanwhile, EVEREST extends the franchise into head-to-head biologic comparison, pitting dupilumab against omalizumab in patients with coexisting CRSwNP and asthma, using endoscopic polyp scores and smell-identification testing as endpoints—reflecting a broader industry trend toward biologic-vs-biologic comparative trials and indirect comparisons (Bucher methodology against METREX, METREO, MATINEE mepolizumab trials) to position products competitively within a crowded type 2 biologics market.
A second, structurally parallel trend is visible in anticoagulation: Regeneron's ROXI-VTE-I and ROXI-VTE-II trials pioneer factor XI (FXI)-targeted monoclonal antibodies (REGN9933A2 and REGN7508Cat) as alternatives to established anticoagulants (enoxaparin, apixaban) for VTE prophylaxis after knee arthroplasty. These trials reflect the same “mechanism-precision” logic seen in the type 2 inflammation programs—REGN9933A2 targets the FXI apple 2 domain to block FXIIa-mediated activation, while REGN7508Cat targets the catalytic domain to block both FXIIa- and thrombin-mediated activation, illustrating iterative epitope engineering within a single therapeutic class. Notably, REGN7508Cat achieved superiority over enoxaparin in ROXI-VTE-II, whereas REGN9933A2 did not in ROXI-VTE-I, exemplifying the incremental, trial-and-error refinement typical of monoclonal antibody-based factor inhibition, with safety consistently benchmarked against clinically relevant non-major bleeding and major bleeding rates.
Across both domains, the trials share a common methodological architecture: large multinational networks (Eastern Europe, North/South America, Australia), rigorous randomization (block randomization, stratification variables), registration transparency via ClinicalTrials.gov, and intention-to-treat analysis as the primary evidentiary standard. The overarching macro-trend is Regeneron/Sanofi's dual strategy of deepening mechanistic and comparative evidence for an approved blockbuster biologic (dupilumab) while simultaneously de-risking a next-generation anticoagulant pipeline (FXI antibodies)—both efforts emphasizing biomarker-driven patient selection (FeNO, eosinophils, IgE) and imaging/functional endpoints to differentiate efficacy beyond traditional composite outcomes, signaling an industry-wide shift toward mechanism-validated, comparator-anchored trial design in immunology and thrombosis alike.